Osecon announced on October 17 that AskGene Pharma, the company's holding subsidiary, and Visara have reached a licensing agreement to license AskGene Pharma's rights and interests in the Class 1 innovative drug ASKG712 project with independent intellectual property rights to Visara for a fee within the licensing area. ASKG712 is clinically used to treat fundus macular disease and is currently in phase IIa clinical research phase in China. Visara is a company incorporated under the laws of the State of Delaware, USA, and is a wholly-owned subsidiary of I-Mab. I-Mab is a global biotechnology company headquartered in the United States, dedicated to developing precise immunotherapy for cancer treatment.

Osecon announced on October 17 that AskGene Pharma, the company's holding subsidiary, and Visara have reached a licensing agreement to license AskGene Pharma's rights and interests in the Class 1 innovative drug ASKG712 project with independent intellectual property rights to Visara for a fee within the licensing area. ASKG712 is clinically used to treat fundus macular disease and is currently in phase IIa clinical research phase in China. Visara is a company incorporated under the laws of the State of Delaware, USA, and is a wholly-owned subsidiary of I-Mab. I-Mab is a global biotechnology company headquartered in the United States, dedicated to developing precise immunotherapy for cancer treatment.